Minimal inhibitory concentrations of linezolid against clinical isolates of coryneform bacteria

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 24, Issue 9, 2005, Pages 612-614

  Funke, G ^a   Nietznik, C ^b  

^a Dr Gartner and Colleagues Laboratory   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ERYTHROMYCIN; LINEZOLID; PENICILLIN G;

ACTINOMYCETALES; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ACETAMIDES; ACTINOMYCETALES; ACTINOMYCETALES INFECTIONS; ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES;

EID: 26844469700     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-005-0014-x     Document Type: Article

References (14)

1. Moellering RC (2003) Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 138:135-142
2. Stevens DL, Dotter B, Madaras-Kelly K (2004) A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2:51-59
3. Funke G, von Graevenitz A, Clarridge III JE, Bernard KA (1997) Clinical microbiology of coryneform bacteria. Clin Microbiol Rev 10:125-159
4. Funke G, Bernard KA (2003) Coryneform gram-positive rods. In: Murray PM, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH (eds). Manual of clinical microbiology. American Society for Microbiology, Washington, DC, pp 472-501
5. MacGregor RR (2000) Corynebacterium diphtheriae. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, PA, pp 2190-2198
6. Clinical and Laboratory Standards Institute (2005) Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. Approved standard M100-S15. CLSI, Wayne, PA
7. Funke G, Pünter V, von Graevenitz A (1996) Antimicrobial susceptibility patterns of some recently established coryneform bacteria. Antimicrob Agents Chemother 40:2874-2878
8. Jones RN, Johnson DM, Erwin ME (1996) In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother 40:720-726
9. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, Hutchinson DK, Barbachyn MR, Brickner SJ (1996) In vitro activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents. Antimicrob Agents Chemother 40:839-845
10. Jones RN, Biedenbach DJ, Anderegg TR (2002) In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species. Diagn Microbiol Infect Dis 42:119-122
11. Johnson AP, Warner M, Malnick H, Livermore DM (2003) Activity of the oxazolidinones AZD2563 and linezolid against Corynebacterium jeikeium and other Corynebacterium spp. J Antimicrob Chemother 51:745-747
12. Sánchez Hernández J, Mora Peris B, Yagüe Guirao G, Gutiérrez Zufiaurre N, Muñoz Bellido JL, Segovia Hernández M, García Rodgríguez JA (2003) In vitro activity of newer antibiotics against Corynebacterium jeikeium, Corynebacterium amycolatum and Corynebacterium urealyticum. Int J Antimicrob Agents 22:492-496
13. Goldstein EJC, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT (2003) In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 47:337-341
14. Wookey A, Turner PJ, Greenhalgh JM, Eastwood M, Clarke J, Sefton C (2004) AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro. Clin Microbiol Infect 10:247-254